Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia

(2015) Masayuki Takase et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol

(2015) Felipe V. Gomes et al.   SCHIZOPHRENIA RESEARCH

l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus

(2013) Jordi Bonaventura et al.   NEUROPHARMACOLOGY

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

(2012) S Miyamoto et al.   MOLECULAR PSYCHIATRY

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

(2012) A. C. Campos et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

(2010) Philip Seeman   CNS Neuroscience & Therapeutics

High-potency cannabis and the risk of psychosis

(2009) Marta Di Forti et al.   BRITISH JOURNAL OF PSYCHIATRY

Dopamine D2Highreceptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil

(2009) Philip Seeman et al.   SYNAPSE

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

(2008) Celia J. A. Morgan et al.   BRITISH JOURNAL OF PSYCHIATRY

Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis

(2008) Daniel Marcellino et al.   NEUROPHARMACOLOGY

Looking for the role of cannabinoid receptor heteromers in striatal function

(2008) Sergi Ferré et al.   NEUROPHARMACOLOGY

Dopamine D2Highreceptors moderately elevated by bifeprunox and aripiprazole

(2008) Philip Seeman   SYNAPSE

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

(2007) R G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY